First Time Loading...

Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 7.42 USD -0.27% Market Closed
Updated: Mar 29, 2024

Editas Medicine Inc
Net Income (Common)

Last Value
3-Years CAGR
5-Years CAGR
Quarterly
Annual
TTM
|

Editas Medicine Inc
Net Income (Common) Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Editas Medicine Inc
NASDAQ:EDIT
Net Income (Common)
$-153.2m
CAGR 3-Years
-10%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$4.8B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$5.7B
CAGR 3-Years
258%
CAGR 5-Years
1%
CAGR 10-Years
6%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$6.7B
CAGR 3-Years
-3%
CAGR 5-Years
-4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.6B
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4B
CAGR 3-Years
4%
CAGR 5-Years
10%
CAGR 10-Years
25%

See Also

What is Editas Medicine Inc's Net Income (Common)?
Net Income (Common)
-153.2m USD

Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Net Income (Common) amounts to -153.2m USD.

What is Editas Medicine Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-7%

Over the last year, the Net Income (Common) growth was 30%. The average annual Net Income (Common) growth rates for Editas Medicine Inc have been -10% over the past three years , -7% over the past five years .